Piramal Pharma Limited (PPLPHARMA)

Name: Piramal Pharma Limited (PPLPHARMA) — storico dei bilanci
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

Storico di ricavi, utili e flussi di cassa dai bilanci ufficiali.

Healthcare · Wall Street (USA) · Ultimo aggiornamento: 2026-09-20

Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities.

Dati chiave

Capitalizzazione di mercato: ₹276 billion
Ricavi (esercizio chiuso a 2026-03-31): ₹87.6B
Utile netto: (₹3.3B)
Margine lordo: 59.1%
Margine netto: -3.7%

Vedi grafici interattivi e bilanci completi →

Conto economico annuale

Conto economico	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Entrate totali	₹87.6B	₹90.6B	₹81.1B	₹70.3B	—
Utile lordo	₹51.8B	₹54.9B	₹48.5B	₹40.3B	—
Risultato Operativo (EBIT)	₹1.5B	₹6.8B	₹4.6B	(₹480M)	—
Reddito netto	(₹3.3B)	₹911M	₹178M	(₹1.9B)	—

Fonte: bilanci pubblici della società (SEC). Verificare su SEC EDGAR prima di fare affidamento su qualsiasi cifra.

Stati patrimoniali, flussi di cassa, dati trimestrali e indici completi nel visualizzatore interattivo di PPLPHARMA. /companies/us/PPLPHARMA

Aziende simili

Le informazioni di questo sito sono solo a scopo educativo e informativo; non costituiscono consulenza finanziaria. Non vengono pubblicati prezzi obiettivo né raccomandazioni.

English version →Tutte le azioni

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.